Literature DB >> 22318644

Platelet-mediated proteolytic down regulation of the anticoagulant activity of protein S in individuals with haematological malignancies.

Ilze Dienava-Verdoold1, Marina R Marchetti, Liane C J te Boome, Laura Russo, Anna Falanga, Harry R Koene, Koen Mertens, Herm Jan M Brinkman.   

Abstract

The natural anticoagulant protein S contains a so-called thrombin- sensitive region (TSR), which is susceptible to proteolytic cleavage. We have previously shown that a platelet-associated protease is able to cleave protein S under physiological plasma conditions in vitro . The aim of the present study was to investigate the relation between platelet-associated protein S cleaving activity and in vivo protein S cleavage, and to evaluate the impact of in vivo protein S cleavage on its anticoagulant activity. Protein S cleavage in healthy subjects and in thrombocytopenic and thrombocythaemic patients was evaluated by immunological techniques. Concentration of cleaved and intact protein S was correlated to levels of activated protein C (APC)-dependent and APC-independent protein S anticoagulant activity. In plasma from healthy volunteers 25% of protein S is cleaved in the TSR. While in plasma there was a clear positive correlation between levels of intact protein S and both APC-dependent and APC-independent protein S anticoagulant activities, these correlations were absent for cleaved protein S. Protein S cleavage was significantly increased in patients with essential thrombocythaemia (ET) and significantly reduced in patients with chemotherapy-induced thrombocytopenia. In ET patients on cytoreductive therapy, both platelet count and protein S cleavage returned to normal values. Accordingly, platelet transfusion restored cleavage of protein S to normal values in patients with chemotherapy-induced thrombocytopenia. In conclusion, proteases from platelets seem to contribute to the presence of cleaved protein S in the circulation and may enhance the coagulation response in vivo by down regulating the anticoagulant activity of protein S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22318644     DOI: 10.1160/TH11-07-0457

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

Review 1.  Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms.

Authors:  Alexandre Guy; Johanne Poisson; Chloe James
Journal:  Leukemia       Date:  2021-03-03       Impact factor: 11.528

Review 2.  Cerebral thrombosis and myeloproliferative neoplasms.

Authors:  Andrea Artoni; Paolo Bucciarelli; Ida Martinelli
Journal:  Curr Neurol Neurosci Rep       Date:  2014-11       Impact factor: 5.081

Review 3.  Are MPNs vascular diseases?

Authors:  Guido Finazzi; Valerio De Stefano; Tiziano Barbui
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

4.  JAK2V617F: Is It Sufficient as a Single Player in Splanchnic Venous Thrombosis?

Authors:  Pratibha Dhiman; Priyanka Saxena
Journal:  Case Rep Hematol       Date:  2015-03-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.